SEARCH

SEARCH BY CITATION

References

  • 1
    Karmali, M. A., Petric, M., Lim, C., Fleming, P. C., and Steele, B. T. (1983) Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet 2, 12991300.
  • 2
    Laing, C. R., Zhang, Y., Gilmour, M. W., Allen, V., Johnson, R., et al. (2012) A comparison of Shiga-toxin 2 bacteriophage from classical enterohemorrhagic Escherichia coli serotypes and the German E. coli O104:H4 outbreak strain. PLoS One 7, e37362.
  • 3
    Hauswaldt, S., Nitschke, M., Sayk, F., Solbach, W., and Knobloch, J. K. (2013) Lessons learned from outbreaks of Shiga toxin producing Escherichia coli. Curr. Infect. Dis. Rep. 15, 49.
  • 4
    Tarr, P. I., Gordon, C. A., and Chandler, W. L. (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365, 10731086.
  • 5
    Johnson, K. E., Thorpe, C. M., and Sears, C. L. (2006) The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin. Infect. Dis. 43, 15871595.
  • 6
    Karch, H., Denamur, E., Dobrindt, U., Finlay, B. B., Hengge, R., et al. (2012) The enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak. EMBO Mol. Med. 4, 841848.
  • 7
    Bielaszewska, M., Mellmann, A., Zhang, W., Kock, R., Fruth, A., et al. (2011) Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect. Dis. 11, 671676.
  • 8
    Smith, W. E., Kane, A. V., Campbell, S. T., Acheson, D. W., Cochran, B. H., et al. (2003) Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect. Immun. 71, 14971504.
  • 9
    Thompson, G. S., Shimizu, H., Homans, S. W., and Donohue-Rolfe, A. (2000) Localization of the binding site for the oligosaccharide moiety of Gb3 on verotoxin 1 using NMR residual dipolar coupling measurements. Biochemistry 39, 1315313156.
  • 10
    Palermo, M. S., Exeni, R. A., and Fernandez, G. C. (2009) Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev. Anti Infect. Ther. 7, 697707.
  • 11
    Neely, M. N. and Friedman, D. I. (1998) Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol. Microbiol. 28, 12551267.
  • 12
    Tyler, J. S., Beeri, K., Reynolds, J. L., Alteri, C. J., Skinner, K. G., et al. (2013) Prophage induction is enhanced and required for renal disease and lethality in an EHEC mouse model. PLoS Pathog. 9, e1003236.
  • 13
    Herold, S., Karch, H., and Schmidt, H. (2004) Shiga toxin-encoding bacteriophages—genomes in motion. Int. J. Med. Microbiol. 294, 115121.
  • 14
    Zhang, X., McDaniel, A. D., Wolf, L. E., Keusch, G. T., Waldor, M. K., et al. (2000) Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181, 664670.
  • 15
    Wagner, P. L., Neely, M. N., Zhang, X., Acheson, D. W., Waldor, M. K., et al. (2001) Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J. Bacteriol. 183, 20812085.
  • 16
    Schmidt, H. (2001) Shiga-toxin-converting bacteriophages. Res. Microbiol. 152, 687695.
  • 17
    Gamage, S. D., Strasser, J. E., Chalk, C. L., and Weiss, A. A. (2003) Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect. Immun. 71, 31073115.
  • 18
    Cornick, N. A., Helgerson, A. F., Mai, V., Ritchie, J. M., and Acheson, D. W. (2006) In vivo transduction of an Stx-encoding phage in ruminants. Appl. Environ. Microbiol. 72, 50865088.
  • 19
    Lankes, H. A., Zanghi, C. N., Santos, K., Capella, C., Duke, C. M., et al. (2007) In vivo gene delivery and expression by bacteriophage lambda vectors. J. Appl. Microbiol. 102, 13371349.
  • 20
    Shimada, O., Ishikawa, H., Tosaka-Shimada, H., and Atsumi, S. (1999) Exocytotic secretion of toxins from macrophages infected with Escherichia coli O157. Cell. Struct. Funct. 24, 247253.
  • 21
    Bentancor, L. V., Bilen, M. F., Mejias, M. P., Fernandez-Brando, R. J., Panek, C. A., et al. (2013) Functional capacity of Shiga-toxin promoter sequences in eukaryotic cells. PLoS One 8, e57128.
  • 22
    Karmali, M. A. (2009) Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int. Suppl. S4S7.
  • 23
    Neupane, M., Abu-Ali, G. S., Mitra, A., Lacher, D. W., Manning, S. D., et al. (2011) Shiga toxin 2 overexpression in Escherichia coli O157:H7 strains associated with severe human disease. Microb. Pathog. 51, 466470.
  • 24
    Los, J. M., Los, M., Wegrzyn, A., and Wegrzyn, G. (2012) Altruism of Shiga toxin-producing Escherichia coli: recent hypothesis versus experimental results. Front. Cell. Infect. Microbiol. 2, 166.
  • 25
    de Sablet, T., Chassard, C., Bernalier-Donadille, A., Vareille, M., Gobert, A. P., et al. (2009) Human microbiota-secreted factors inhibit shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7. Infect. Immun. 77, 783790.
  • 26
    Fernandez-Brando, R. J., Miliwebsky, E., Mejias, M. P., Baschkier, A., Panek, C. A., et al. (2012) Shiga toxin-producing Escherichia coli O157: H7 shows an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host. J. Med. Microbiol. 61, 852859.
  • 27
    Malyukova, I., Murray, K. F., Zhu, C., Boedeker, E., Kane, A., et al. (2009) Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G78G92.
  • 28
    Besser, R. E., Griffin, P. M., and Slutsker, L. (1999) Escherichia coli O157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Annu. Rev. Med. 50, 355367.
  • 29
    Philpott, D. J., Ackerley, C. A., Kiliaan, A. J., Karmali, M. A., Perdue, M. H., et al. (1997) Translocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. Am. J. Physiol. 273, G1349G1358.
  • 30
    Schuller, S., Frankel, G., and Phillips, A. D. (2004) Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. Cell. Microbiol. 6, 289301.
  • 31
    Hurley, B. P., Thorpe, C. M., and Acheson, D. W. (2001) Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect. Immun. 69, 61486155.
  • 32
    Zumbrun, S. D., Hanson, L., Sinclair, J. F., Freedy, J., Melton-Celsa, A. R., et al. (2010) Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide. Infect. Immun. 78, 44884499.
  • 33
    Muthing, J., Schweppe, C. H., Karch, H., and Friedrich, A. W. (2009) Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb. Haemost. 101, 252264.
  • 34
    Griffin, P. M., Olmstead, L. C., and Petras, R. E. (1990) Escherichia coli O157:H7-associated colitis. A clinical and histological study of 11 cases. Gastroenterology 99, 142149.
  • 35
    Rodney, A. M. L., Francis DH. (1998) Overview of animal models. In Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains. (Kaper, J. B. and O'Brien AD, eds.). pp. 249260, Am Soc Microbiol, Washington DC.
  • 36
    Keenan, K. P., Sharpnack, D. D., Collins, H., Formal, S. B., and O'Brien, et al. (1986) Morphologic evaluation of the effects of Shiga toxin and E. coli Shiga-like toxin on the rabbit intestine. Am. J. Pathol. 125, 6980.
  • 37
    Fiorito, P., Burgos, J. M., Miyakawa, M. F., Rivas, M., Chillemi, G., et al. (2000) Effect of Shiga toxin 2 on water and ion transport in human colon in vitro. Dig. Dis. Sci. 45, 480486.
  • 38
    Creydt, V. P., Miyakawa, M. F., Martin, F., Zotta, E., Silberstein, C., et al. (2004) The Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Braz. J. Med. Biol. Res. 37, 799808.
  • 39
    Bielaszewska, M., Clarke, I., Karmali, M. A., and Petric, M. (1997) Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect. Immun. 65, 25092516.
  • 40
    Trachtman, H., Austin, C., Lewinski, M., and Stahl, R. A. (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat. Rev. Nephrol. 8, 658669.
  • 41
    Brigotti, M. (2012) The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety? Toxins (Basel) 4, 157190.
  • 42
    Geelen, J. M., van der Velden, T. J., van den Heuvel, L. P., and Monnens, L. A. (2007) Interactions of Shiga-like toxin with human peripheral blood monocytes. Pediatr. Nephrol. 22, 11811187.
  • 43
    Johannes, L. and Romer, W. (2010) Shiga toxins—from cell biology to biomedical applications. Nat. Rev. Microbiol. 8, 105116.
  • 44
    Zoja, C., Buelli, S., and Morigi, M. (2010) Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr. Nephrol. 25, 22312240.
  • 45
    Petruzziello, T. N., Mawji, I. A., Khan, M., and Marsden, P. A. (2009) Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int. Suppl. S17S19.
  • 46
    Paton, J. C. and Paton, A. W. (2006) Shiga toxin ‘goes retro’ in human primary kidney cells. Kidney Int. 70, 20492051.
  • 47
    Thorpe, C. M., Hurley, B. P., Lincicome, L. L., Jacewicz, M. S., Keusch, G. T., et al. (1999) Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect. Immun. 67, 59855993.
  • 48
    Wagner, P. L., Acheson, D. W., and Waldor, M. K. (2001) Human neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli. Infect. Immun. 69, 19341937.
  • 49
    Bielaszewska, M. and Karch, H. (2005) Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb. Haemost. 94, 312318.
  • 50
    Chandler, W. L., Jelacic, S., Boster, D. R., Ciol, M. A., Williams, G. D., et al. (2002) Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N. Engl. J. Med. 346, 2332.
  • 51
    Fernandez, G. C., Gomez, S. A., Rubel, C. J., Bentancor, L. V., Barrionuevo, P., et al. (2005) Impaired neutrophils in children with the typical form of hemolytic uremic syndrome. Pediatr. Nephrol. 20, 13061314.
  • 52
    Gomez, S. A., Abrey-Recalde, M. J., Panek, C. A., Ferrarotti, N. F., Repetto, M. G., et al. (2013) The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of hemolytic uremic syndrome. Clin. Exp. Immunol. 173, 463472
  • 53
    Stahl, A. L., Sartz, L., and Karpman, D. (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117, 55035513.
  • 54
    Ramos, M. V., Fernandez, G. C., Patey, N., Schierloh, P., Exeni, R., et al. (2007) Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome. Blood 109, 24382445.
  • 55
    Ramos, M. V., Auvynet, C., Poupel, L., Rodero, M., Mejias, M. P., et al. (2012) Chemokine receptor CCR1 disruption limits renal damage in a murine model of hemolytic uremic syndrome. Am. J. Pathol. 180, 10401048.
  • 56
    Orth, D., Khan, A. B., Naim, A., Grif, K., Brockmeyer, J., et al. (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 182, 63946400.
  • 57
    Paixao-Cavalcante, D., Botto, M., Cook, H. T., and Pickering, M. C. (2009) Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice. Clin. Exp. Immunol. 155, 339347.
  • 58
    Proulx, F., Wagner, E., Toledano, B., Decaluwe, H., Seidman, E. G., et al. (2003) Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome. Clin. Exp. Immunol. 133, 360363.
  • 59
    Menne, J., Nitschke, M., Stingele, R., Abu-Tair, M., Beneke, J., et al. (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case–control study. BMJ 345, e4565.
  • 60
    Lapeyraque, A. L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., et al. (2011) Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 364, 25612563.
  • 61
    Wong, C. S., Mooney, J. C., Brandt, J. R., Staples, A. O., Jelacic, S., et al. (2012) Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin. Infect. Dis. 55, 3341.
  • 62
    Bielaszewska, M., Idelevich, E. A., Zhang, W., Bauwens, A., Schaumburg, F., et al. (2012) Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob. Agents Chemother. 56, 32773282.
  • 63
    Nishikawa, K., Watanabe, M., Kita, E., Igai, K., Omata, K., et al. (2006) A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin. FASEB J. 20, 25972599.
  • 64
    Tsutsuki, K., Watanabe-Takahashi, M., Takenaka, Y., Kita, E., and Nishikawa, K. (2013) Identification of a peptide-based neutralizer that potently inhibits both Shiga toxins 1 and 2 by targeting specific receptor-binding regions. Infect, Immun. 81, 21332138.
  • 65
    Lee, L., Abe, A., and Shayman, J. A. (1999) Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274, 1466214669.
  • 66
    Kolter, T., Proia, R. L., and Sandhoff, K. (2002) Combinatorial ganglioside biosynthesis. J. Biol. Chem. 277, 2585925862.
  • 67
    Silberstein, C., Pistone Creydt, V., Gerhardt, E., Nunez, P., and Ibarra, C. (2008) Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2. Pediatr. Nephrol. 23, 19811990.
  • 68
    Amaral, M. M., Sacerdoti, F., Jancic, C., Repetto, H. A., Paton, A. W., et al. (2013) Action of Shiga toxin type-2 and Subtilase cytotoxin on human microvascular endothelial cells. PloS One 8, e70431.
  • 69
    Silberstein, C., Lucero, M., Zotta, E., Copeland, D. P., Lingyun, L. I., et al. (2011) A Glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of Shiga toxin 2. Pediatr. Res. 69, 390394.
  • 70
    Jandhyala, D. M., Ahluwalia, A., Obrig, T., and Thorpe, C. M. (2008) ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell. Microbiol. 10, 14681477.
  • 71
    Stone, S. M., Thorpe, C. M., Ahluwalia, A., Rogers, A. B., Obata, F., et al. (2012) Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinib. Front. Cell. Infect. Microbiol. 2, 135.
  • 72
    Mukhopadhyay, S. and Linstedt, A. D. (2012) Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 335, 332335.
  • 73
    Allen, K. J., Rogan, D., Finlay, B. B., Potter, A. A., and Asper, D. J. (2011) Vaccination with type III secreted proteins leads to decreased shedding in calves after experimental infection with Escherichia coli O157. Can. J. Vet. Res. 75, 98105.